ReviewFrontiers in immunology2022
Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data.Virology journal · 2025Pooled it
- The epidemiologic and economic burden of dengue in Singapore: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life.Human vaccines & immunotherapeutics · 2023Trial
- A Capabilities, Opportunities, and Motivations behavioral analysis of healthcare professionals concerning dengue vaccination in selected countries from Latin America and Asia Pacific.Human vaccines & immunotherapeutics · 2026Article
- Unresolved questions in pediatric dengue: from disease mechanisms to prevention.Current opinion in infectious diseases · 2026Review
- Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk.Vaccine · 2026Article
- Designing potent and immunogenic epitope based peptide vaccine against all serotypes of DENV via structural, physico-chemical and immunoinformatics-based approaches.Scientific reports · 2026Article
- Dengue virus genetic diversity and lineage dynamics in Thailand: implications for surveillance and vaccine implementation.Virology journal · 2026Article
- Safety of a tetravalent live dengue virus vaccine in children responding to one serotype only.JCI insight · 2026Article
- CD8+ T cells and Humoral Immunity Influence the Development of Antibody-Dependent Enhancement: Implications for Vaccine Design.bioRxiv : the preprint server for biology · 2026Article
- Epitope dynamics and antigenic shifts in dengue virus serotype 2 cosmopolitan genotype with structural changes in Bangladesh from 2017 to 2023.Scientific reports · 2026Article
- The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine.NPJ vaccines · 2026Review
- Transforming therapeutics through biomaterials: A comprehensive insight into biomaterials' role in effective drug delivery and healthcare advancement.Biomaterials translational · 2026Review
- Dengue virus introduction and 2025 outlook: scenario-based evaluation of vaccination impact using mathematical modeling.Cadernos de saude publica · 2026Article
- Dengue Virus and the Host Immune System: A Battle of Immune Modulation, Response and Evasion.Pathogens (Basel, Switzerland) · 2025Review
- Review
- Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue.Vaccines · 2025Review
- From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity.Vaccines · 2025Review
- Pathogenesis and clinical management of arboviral diseases.World journal of virology · 2025Review
- In Silico Evaluation of Potential Hit Molecules Against Multiple Serotypes of Dengue Virus Envelope Glycoprotein.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is the most common arboviral disease caused by one of four distinct but closely related dengue viruses (DENV) and places significant economic and public health burdens in the endemic areas. A dengue vaccine will be important in advancing disease control. However, the effort has been challenged by the requirement to induce effective protection against all four DENV serotypes and the potential adverse effect due to the phenomenon that partial immunity to DENV may worsen the symptoms upon subsequent heterotypic infection. Currently, the most advanced dengue vaccines are all tetravalent and based on recombinant live attenuated viruses. CYD-TDV, developed by Sanofi Pasteur, has been approved but is limited for use in individuals with prior dengue infection. Two other tetravalent live attenuated vaccine candidates: TAK-003 by Takeda and TV003 by National Institute of Allergy and Infectious Diseases, have completed phase 3 and phase 2 clinical trials, respectively. This review focuses on the designs and evaluation of TAK-003 and TV003 vaccine candidates in humans in comparison to the licensed CYD-TDV vaccine. We highlight specific lessons from existing studies and challenges that must be overcome in order to develop a dengue vaccine that confers effective and balanced protection against all four DENV serotypes but with minimal adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.